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Spranger and colleagues reported recently in Nature an inverse relationship between melanoma intrinsic
b-catenin signaling and intratumoral T cell infiltration, providing an explanation for potential mechanisms
of T cell exclusion. Further insights are needed into the mechanisms leading to a lack of T cell infiltration
of cancers and primary immune resistance.After decades of efforts, the war on cancer
has reached an exciting new turning point
with the promise of long-term remissions
in patients with different cancer histologies
treatedwith immune checkpoint inhibitors.
It reflects a fundamental change by fully
utilizing the power of the human immune
system to control and eradicate cancer.
Sustained responses have been reported
beyond the traditionally ‘‘immunotherapy
sensitive’’ tumor types such as melanoma
or renal cell carcinoma, evidenced by the
USFoodandDrugAdministrationapproval
of the anti-PD-1 antibody nivolumab to
treat the squamous subtype of non-small
cell lung cancer as a second-line therapy.
Full pipelines of immune modulatory
agents are in different stages of clinical
development for a wide variety of tumor
types. It is still unclear, however, why only
a percentage of patients within the same
tumor type respond to the therapy and
why certain tumors do not respond at all.
Studying the immune resistance mecha-
nisms in these patients and tumor types
would pave the way to the rational design
of combination strategies to improve
efficacy.The Wnt/b-catenin pathway is crucial in
embryonic development and adult tissue
homeostasis, including hematopoiesis,
cell migration, and wound repair (Kahn,
2014). Aberrant regulation of this pathway
has been linked to cancer development,
more aggressive behavior, and worse
prognosis in several types of cancers.
Mutations of b-catenin have been des-
cribed in melanoma cell lines (Rubinfeld
et al., 1997), and active WNT/b-catenin
signaling was reported in one third of
melanoma tumors. However, its signifi-
cance is a matter of debate, because
melanomas with a b-catenin signature
have been associated with lower prolifer-
ative index (Chien et al., 2009), more
favorable prognosis, and less aggressive
disease (Bachmann et al., 2005), adding
to the complexity of this topic.
In a recent publication in Nature,
Spranger et al., (2015) demonstrated
that tumor-intrinsic b-catenin signaling
might result in the lack of T cell
infiltration in melanoma models and in
patient-derived biopsies. As a first step,
the authors analyzed microarray gene
expression data from 266 human cuta-neous melanoma samples acquired from
the public domain and categorized these
samples into ‘‘T cell inflamed’’ and ‘‘non-
T cell-inflamed’’ subtypes based on rele-
vant gene expression. Pathway analysis
suggested the association of active b-cat-
enin signaling with the non-T cell-inflamed
cohort, which was a novel observation.
The authors then used previously es-
tablished genetically engineered mouse
models driven by conditional BRAFV600E
activation and PTEN deletion (BRAFV600E/
PTEN/), compared with an additional
stabilized b-catenin (BRAFV600E/PTEN//
Bcat-STA) melanoma mouse model
(Damsky et al., 2011). Melanomas in
these mice can be induced by local appli-
cation of tamoxifen, and the BRAFV600E/
PTEN//Bcat-STA phenotype was previ-
ously reported to be more aggressive with
high metastatic potential (Damsky et al.,
2011). Melanomas arising from mice with
active b-catenin were associated with
almost complete absence of T cells, and
the few remaining intratumoral T cells
showed predominantly a naive phenotype
with low PD-1, PD-L1, and LAG3 ex-
pression. When a neo-antigen (SIY) wasll 27, June 8, 2015 ª2015 Elsevier Inc. 749
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nomas of these mice, adoptively trans-
ferred T cells with SIY T cell receptor
(TCR) accumulated in the BRAFV600E/
PTEN/ tumors, but not in the
BRAFV600E/PTEN//Bcat-STA tumors,
indicating defective homing of target-spe-
cific T cells in the tumors. The authors
concluded from this data that intrinsic
tumor b-catenin signaling prevents early
T cell priming, although alternative mech-
anisms could be provided. They then
analyzed the Batf3-lineage dendritic cells
(DC) in the tumors, given its crucial role
in presenting tumor antigens to CD8+
T cells. Indeed, CD8a+ (skin-derived) and
CD103+ (lymph node-derived) DCs were
almost absent, with reduced IFN-b cyto-
kine expression in tumors from the
BRAFV600E/PTEN//Bcat-STA model,
but not in its counterpart without b-catenin
stabilization. Interestingly, BRAFV600E/
PTEN//Batf3/ bonemarrow chimeras
manifested similarly decreased T cell infil-
tration, and intratumoral injection of acti-
vated DCs by poly I:C could restore
T cell infiltration in BRAFV600E/PTEN//
Bcat-STA tumors.
Further gene expression profiling from
tumors of these two genotypes revealed
five chemokines differentially expressed,
with four of these showing lower levels
in the BRAFV600E/PTEN//Bcat-STA tu-
mors (CCL3, CXCL1, CXCL2, and CCL4)
associated with a lack of expression of
the corresponding chemokine receptor
CCR5 by DCs isolated from these tumors.
CCR5 was linked to migratory capacity
of CD8a+ DCs. In vitro migration assays
showed DC migration in response to re-
combinant murine CCL4 and the superna-
tant of cell lines derived from the
BRAFV600E/PTEN/, but no DCmigration
was observed with the BRAFV600E/
PTEN//Bcat-STA tumors. Further CHIP
assay revealed that the mechanism by
which b-catenin signaling prevents CCL4
expression might be through binding of
ATF3 (downstream of b-catenin) to the
CCL4 promoter region in BRAFV600E/
PTEN//Bcat-STA cells. Knock-down
of b-catenin or ATF3 restored CCL4 pro-
duction in these cells. This observation
was also confirmed in human melanoma750 Cancer Cell 27, June 8, 2015 ª2015 Elsecell lines with low or high b-catenin
expression, and gene expression analysis
of human melanoma metastasis showed
inverse correlation of Batf3-lineage DC
marker expression and gain-of-function
mutations in b-catenin.
In the end of the study, the authors
explored the therapeutic relevance by
treating both mouse models with a com-
bination of anti-CTLA-4 and anti-PD-L1
antibodies, which induced a significant
delay in tumor growth in the BRAFV600E/
PTEN/ model, but not in the
BRAFV600E/PTEN//Bcat-STA model.
Intratumoral injection of activated DCs
into the BRAFV600E/PTEN//Bcat-STA
tumors, on the other hand, could partially
restore the therapeutic effect of anti-
CTLA-4 and anti-PD-L1 antibodies. It is
unclear, however, why the authors did
not include the therapeutic effects of
single agent controls. Based on this
work, the lack of efficacy may stem from
the priming phase (which is the primary
target of CTLA-4 blockade) or the effector
phase of an anti-tumor T cell cytotoxic
response (the primary target of PD-1
blockade).
The inverse relationship of active
b-catenin signaling and T cell infiltration
in both human melanoma samples and
transgenic melanoma mouse models by
Spranger and colleagues provides a first
insight into a potential new mechanism
of immune resistance. Further evidence
to support this notion, but not provided
by this paper, would be a correlation of
the b-catenin signaling with a differential
responsiveness with immune modulatory
therapies in humans. Although the thera-
peutic potential was demonstrated in a
transgenic mouse model, similar obser-
vations need to be confirmed in animal
models of different genetic background
(such as BRAFWT/PTEN//Bcat-STA,
BRAFV600E/PTENWT/Bcat-STA, or others)
before generalized application. The Wnt
signaling pathway has been shown to
be critical in lymphopoiesis and hemato-
poiesis (Staal et al., 2008), including
T cell development and DC maturation.
One potential concern of transgenic
mouse models is if the tissue-specific
promoter is leaky or if there was disrup-vier Inc.tion of the genome at the embryonic level
when inserting the transgene, it might
compromise the development of an
intact immune system. Spranger and
collaborators described a lack of CCR5
expression on DCs in BRAFV600E/
PTEN//Bcat-STA tumors, but no data
indicated whether DC isolated from the
spleens of the same mice had the same
defect. Using syngeneic mouse models
with cell lines derived from these trans-
genic tumors would be helpful in this
situation. Finally, given the previous
observation that active WNT/b-catenin
signaling was associated with a lower
proliferative index and more favorable
prognosis in human samples, but had
the opposite effect in this mouse model,
the exact role of this pathway plays in
the tumor immune microenvironment re-
mains to be fully determined.ACKNOWLEDGEMENTS
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